Steve Bryson, PhD,  science writer—

One year of Trikafta treatment for adults with cystic fibrosis (CF) post-lung transplant resulted in only limited improvements in sinus and digestive problems and was not well-tolerated, a small study found. In fact, among the 13 patients in the study, the discontinuation rate for the triple-combination therapy was 38.4%.

More frequent lung function tests in young people with cystic fibrosis (CF) markedly increased the diagnoses of pulmonary exacerbations — bouts of lung symptom worsening — leading to improved treatment and better lung function, a Brazilian study suggested. “The impact of such a simple initiative can be substantial and…

Adults with cystic fibrosis (CF) who live with recurrent nose and sinus inflammation — called chronic rhinosinusitis, or CRS — have a poor health-related quality of life (HRQoL), and need improved diagnosis and treatment, a large Canadian study concluded. These findings were especially true for patients who experienced severe…

Lupin has received tentative approval from the U.S. Food and Drug Administration (FDA) to market ivacaftor tablets, a generic version of the cystic fibrosis (CF) therapy Kalydeco. The company’s request came in the form of an abbreviated new drug application (ANDA), containing data submitted for review and approval…

Stool consistency and frequency were healthy for the majority of infants with cystic fibrosis (CF) in the first year of life, according to an analysis of data from the BONUS study. Stool consistency and frequency were not associated with pain, while infants exclusively fed with formula or who received…

A detailed analysis of lung tissue of cystic fibrosis (CF) patients found specific changes to the extracellular matrix (ECM), the three-dimensional network of molecules and proteins outside the cell that supports lung function, a study showed. Drivers of ECM breakdown may act as therapeutic targets or biomarkers to monitor…

ReCode Therapeutics’ investigational aerosolized RNA-based therapies for cystic fibrosis (CF) restored CFTR function, the defective protein in CF, in patient-derived lung cells. Delivered by the company’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform, the therapy showed no signs of toxicity in epithelial cells that line the airways.

LungFit GO, inhaled nitric oxide (NO) that can be self-administered at home, was well tolerated and improved various quality of life measures, according to recent data from a pilot study that evaluated the experimental treatment in adults with or without cystic fibrosis (CF). The ongoing study involves people…

For the first time, bacteriophages — viruses that kill bacteria — eliminated an antibiotic-resistant mycobacterial lung infection in a man with advanced cystic fibrosis (CF) lung disease, a study reported. As a result, the patient was able to undergo a successful lung transplant after one year of bacteriophage treatment.

Cases of severe COVID-19 remained low during the first year of the pandemic in people in France with cystic fibrosis (CF), a study reported. Patients with severe lung disease or CF-related diabetes, as well as those who underwent a lung transplant, however, were at a higher risk of…